NCT02643862View on ClinicalTrials.gov

Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 18, 2015

Primary Completion Date

August 20, 2016

Study Completion Date

August 20, 2016

Conditions
Food Allergy
Interventions
DRUG

Xolair

Xolair is a monoclonal antibody approved by the FDA for asthma and chronic urticaria

DRUG

Placebo

Placebo

Trial Locations (1)

94040

Sean N Parker Allergy Reseach Center at Stanford University, Mountain View

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Stanford University

OTHER

NCT02643862 - Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients | Biotech Hunter | Biotech Hunter